Equity in clinical trials for hepatitis B

Tim Mitchell¹, Jeremy S Nayagam², Mzamo N Mbelle³, Kenneth Kabagambe⁴, Kosh Agarwal²

Affiliations

¹ Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA 6847, Australia. Electronic address: tim.mitchell@health.wa.gov.au.
² Institute of Liver Studies, King's College Hospital, London, UK.
³ Institute of Liver Studies, King's College Hospital, London, UK; Division of Gastroenterology, Department of Internal Medicine, University of Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
⁴ The National Organisation for People Living with Hepatitis B, Kampala, Uganda.

PMID: 38734004
DOI: 10.1016/S2468-1253(24)00083-9

Comment

Equity in clinical trials for hepatitis B

Tim Mitchell et al. Lancet Gastroenterol Hepatol. 2024 Jun.

. 2024 Jun;9(6):501-502.

doi: 10.1016/S2468-1253(24)00083-9.

Authors

Tim Mitchell¹, Jeremy S Nayagam², Mzamo N Mbelle³, Kenneth Kabagambe⁴, Kosh Agarwal²

Affiliations

¹ Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA 6847, Australia. Electronic address: tim.mitchell@health.wa.gov.au.
² Institute of Liver Studies, King's College Hospital, London, UK.
³ Institute of Liver Studies, King's College Hospital, London, UK; Division of Gastroenterology, Department of Internal Medicine, University of Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa.
⁴ The National Organisation for People Living with Hepatitis B, Kampala, Uganda.

PMID: 38734004
DOI: 10.1016/S2468-1253(24)00083-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

KA has received research grants and honoraria from Gilead, GSK, and Abbott; is a consultant for Aligos, AusperBio, Gilead, GSK, Grifols, Novotech, PrecisionBio, Surrozen, Tune, and Vir; and participates on an advisory board for DrugFarm. All other authors declare no competing interests.

Comment on

Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection.
Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E, Okanda D, Aliyan N, Van Schalkwyk M, Anderson M, Ocama P, Maponga T, Torimiro J, Iwuji C, Ndung'u T, Matthews PC, Taljaard J. Delphin M, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):383-392. doi: 10.1016/S2468-1253(23)00315-1. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367632 Free PMC article. Review.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Equity in clinical trials for hepatitis B

Affiliations

Equity in clinical trials for hepatitis B

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources